In an aspect to achieve the above object, the present disclosure provides a pharmaceutical combination preparation comprising a first layer comprising telmisartan or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, and calcium silicate; and a second layer comprising (S)-amlodipine or a pharmaceutically acceptable salt thereof.
The pharmaceutical combination preparation of the present disclosure comprises microcrystalline cellulose and calcium silicate in the first layer to improve the hygroscopic properties of the first layer comprising telmisartan and, at the same time, not to influence the stability of (S)-amlodipine contained in the second layer.
In the present disclosure, "telmisartan" is a compound with the chemical name of 2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzothiazol-2-yl)-2-propyl-1H-1,3-benzothiazol-1-yl]methyl}phenyl)benzoic acid and is represented by the following Formula 1:
[Formula 1]
In the present disclosure, telmisartan may be commercially available or synthesized by any method known in the art, but not limited thereto.
Telmisartan of the present disclosure may be used in various forms such as a free acid of telmisartan or a pharmaceutically acceptable salt thereof, an isomer, a racemate, a hydrate, a solvate, etc. as long as the same pharmacological activity is maintained.
The pharmaceutically acceptable salt comprises a salt derived from a pharmaceutically acceptable acid or base. As used herein, the term "pharmaceutically acceptable salt" refers to any organic or inorganic addition salt whose concentration has effective action because it is relatively non-toxic and harmless to the patients and whose side effects do not degrade the beneficial efficacy of the active ingredient.
Preferably, the pharmaceutically acceptable salt of telmisartan of the present disclosure may be a sodium salt, a potassium salt, a magnesium salt, or a calcium salt of telmisartan, but not limited thereto.
More preferably, the pharmaceutical combination preparation of the present disclosure comprises a free acid of telmisartan.
In the present disclosure, isomer includes optical isomer, diastereomer and mixture of both.
Telmisartan is prescribed for essential hypertension and is a drug that selectively acts on an angiotensin II receptor, which acts as a potent vasoconstrictor in the renin-angiotensin-aldosterone system and, in particular, selectively acts on an AT1 receptor involved in the main physiological actions such as vasoconstriction, etc. Telmisartan has a blood pressure-lowering effect continuously for 24 hours, and thus the drug taken the day before has the effect of regulating blood pressure until the next morning when blood pressure rapidly increases. Furthermore, the renal clearance of telmisartan is less than 2%, and thus it is not necessary to adjust the dose in patients with mild to severe renal impairment. According to the recent research results, the risk of occurrence of side effects such as hyperpotassemia is very lower than other ARBs (Park Rae Woong, American Journal of Cardiovascular Drugs, (2012)), and thus it has been evaluated as the best drug among the existing ARBs.
Telmisartan has very poor solubility in aqueous systems at the physiological pH range (pH 1 to 7) of the gastrointestinal tract, and thus it is preferred to use an alkalizing agent to improve the solubility and solubilization of telmisartan for the formulation.
Therefore, the first layer of the pharmaceutical combination preparation according to the present disclosure preferably comprises an alkalizing agent. Suitable alkalizing agents that can be used include metal hydrates, basic amino acids, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, sodium hydrogen phosphate, and mixtures thereof. Examples of the metal hydrate may include sodium hydroxide, calcium hydroxide, etc.; and examples of the basic amino acid may include arginine, ricin, meglumine (N-methyl-D-glucamine), etc. Preferably, the pharmaceutical combination preparation of the present disclosure comprises dried sodium carbonate.
Meanwhile, the alkalizing agent has deliquescence and hygroscopic properties, and thus when a preparation comprising an alkalizing agent is exposed to water or moisture, the preparation is sticky or melted, which is very problematic.
Meanwhile, the second layer of the pharmaceutical combination preparation according to the present disclosure preferably comprises (S)-amlodipine as an active ingredient.
In the present disclosure, "(S)-amlodipine" is a compound with the chemical name of 3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate and is represented by the following Formula 2:
[Formula 2]
In the present disclosure, (S)-amlodipine may be commercially available or synthesized by any method known in the art, but not limited thereto.
(S)-amlodipine of the present disclosure may be used in various forms such as a free base of (S)-amlodipine or a pharmaceutically acceptable salt thereof, an isomer, a racemate, a hydrate, a solvate, etc. as long as the same pharmacological activity is maintained.
The pharmaceutically acceptable salt comprises a salt derived from a pharmaceutically acceptable acid or base. As used herein, the term "pharmaceutically acceptable salt" refers to any organic or inorganic addition salt whose concentration has effective action because it is relatively non-toxic and harmless to the patients and whose side effects do not degrade the beneficial efficacy of the active ingredient.
Preferably, the pharmaceutically acceptable salt of (S)-amlodipine of the present disclosure may be (S)-amlodipine besylate, (S)-amlodipine maleate, (S)-amlodipine orotate, (S)-amlodipine camsylate, (S)-amlodipine adipate, or (S)-amlodipine mesylate, but not limited thereto.
More preferably, the pharmaceutical combination preparation of the present disclosure comprises (S)-amlodipine besylate.
Amlodipine is one of the calcium channel blockers (CCBs) and is a very useful calcium channel blocker that has a half-life of 30 to 50 hours and exhibits activity continuously over a long period of time. Amlodipine blocks the influx of calcium into the vascular smooth muscle to induce peripheral arterial vasodilation, resulting in a decrease in blood pressure, and is effective in angina pectoris due to vasoconstriction. Amlodipine is a chiral compound with a chiral center, and it is known that the (S)-optical isomer of amlodipine is a potent calcium channel blocker that has higher activity than an isomeric mixture (in racemic form) (Arrowsmith et al., J. Med. Chem., 29, 1696 (1986)), and the (R)-optical isomer has activity 1,000 times lower than the (S)-optical isomer and has a kinin-mediated nitric oxide mechanism that is likely to be associated with side effects (Hintze et al., J. Cardiovasc. Pharmacol., 39(2):208-14 (2002)). Therefore, the isolation and administration of (S)-amlodipine, a pure optical isomer, increases the receptor binding selectivity, which shows efficacy compared to amlodipine racemate, and reduces the dose by about half, reducing the interaction between the drugs and the possibility of side effects.
However, it is known that in view of the stability, the (S)-amlodipine is considerably more unstable than the racemate thereof, the degradation of (S)-amlodipine is experimentally faster than the racemate, and the content of related compounds also increases due to an increase in degradation products. This is because the form of thermodynamically isolated optical isomers is unstable (Hadzidedic et al., J. Pharm. Dev. Technol., 19(8): 930.941 (2014)).
The (S)-amlodipine is easily hydrolyzed by the alkalizing agent used for the solubility and solubilization of telmisartan, resulting in reduced stability of amlodipine.
The pharmaceutical combination preparation of the present disclosure has the advantage of improving both the hygroscopic properties of telmisartan and the reduced stability of (S)-amlodipine. Specifically, the present disclosure provides the improvement of the hygroscopic properties in the first layer of pharmaceutical combination preparation that comprises microcrystalline cellulose as an excipient and calcium silicate as an adsorbent. At the same time, it characterized in that the addition of microcrystalline cellulose and calcium silicate in the first layer does not influence the stability of the (S)-amlodipine contained in the second layer.
In a specific experimental example, the degree of hygroscopic properties was tested under accelerated conditions (75% humidity, 40 °C temperature) and, as a result, after 1 day, the commercially available Micardis tablets were melted beyond recognition, while the tablets comprising microcrystalline cellulose were very little changed, resulting in significant improvement of hygroscopic properties (Experimental Example 1).
Preferably, in the pharmaceutical combination preparation of the present disclosure, the weight ratio of telmisartan or a pharmaceutically acceptable salt thereof to microcrystalline cellulose is 10:25 to 10:35.
Preferably, the pharmaceutical combination preparation of the present disclosure may comprise microcrystalline cellulose in an amount of 50 to 60 wt% with respect to the total weight of the first layer.
In a specific experimental example, an appropriate content range of microcrystalline cellulose contained in the preparation was determined and, as a result, it was found that when the weight ratio of telmisartan to microcrystalline cellulose was 10:25 and 10:30, the friability of tablets was small, and the maximum hardness of tablets was high; in particular, when the amount of microcrystalline cellulose contained in the preparation was higher, the maximum hardness of tablets increased, and the friability of tablets decreased.
Preferably, in the pharmaceutical combination preparation of the present disclosure, the weight ratio of telmisartan or a pharmaceutically acceptable salt thereof to calcium silicate is 10:1 to 10:6.
More preferably, in the pharmaceutical combination preparation of the present disclosure, the weight ratio of telmisartan or a pharmaceutically acceptable salt thereof to microcrystalline cellulose is 10:25 to 10:30, and the weight ratio of telmisartan or a pharmaceutically acceptable salt thereof to calcium silicate is 10:1 to 10:5.
More particularly, in the pharmaceutical combination preparation of the present disclosure, the weight ratio of telmisartan or a pharmaceutically acceptable salt thereof to calcium silicate is 10:2 to 10:3.
In a specific experimental example, the improvement of hygroscopic properties and the influence on the stability of the (S)-amlodipine layer depending on the amount of calcium silicate in the preparation were tested. As a result, it was found that the addition of calcium silicate to the telmisartan layer was effective for the improvement of hygroscopic properties, but when the amount of calcium silicate added was increased, the content of (S)-amlodipine-related compounds was also increased. Therefore, it was found that an appropriate content of calcium silicate contained in the preparation, which improves the hygroscopic properties of the telmisartan layer and does not significantly degrade the stability of the (S)-amlodipine layer, that is, the weight ratio of telmisartan or a pharmaceutically acceptable salt thereof to calcium silicate was preferably 10:1 to 10:5, more preferably, 10:2 to 10:3.
The pharmaceutical combination preparation of the present disclosure may further comprise at least one pharmaceutically acceptable additive. Any additives that are well known in the art may be used as long as they do not cause an interaction with telmisartan or a pharmaceutically acceptable salt thereof and (S)-amlodipine or a pharmaceutically acceptable salt thereof and does not disturb the efficacy.
The pharmaceutically acceptable additive may be at least one selected from the group consisting of diluents, binders, disintegrants, lubricants, and coating agents, but not limited thereto.
As used herein, the term "diluent" refers to any inert substance that is used as a filler to create desired bulk, flow properties, and compression characteristics in the preparation of solid dose formulations. Examples of the diluent may include lactose hydrate, anhydrous lactose, white sugar, corn starch, dibasic calcium phosphate, etc., but not limited thereto.
As used herein, the term "excipient" refers to a substance that is added to give appropriate hardness and shape to the medicinal preparation or give certain volume and weight to the medicinal preparation to have a size that is easy to handle when the amount of the main ingredient is small. Examples of the excipient may include sugar derivatives such as mannitol, sorbitol, etc.; starches such as corn starch, potato starch, etc.; cellulose derivatives such as low substituted hydroxypropylcellulose, methylcellulose etc.; inorganic excipients such as calcium carbonate, etc., but not limited thereto.
In the present disclosure, the terms "diluent" and "excipient" can be interchangeably used.
As used herein, the term "binder" refers to a substance that can impart elasticity and adhesion to increase the strength of the resulting preparation, particularly, the strength of the resulting tablets. Examples of the binder may include carboxymethylcellulose-sodium (CMC-Na), starch solutions, polyvinylpyrrolidone (PVP), gum arabic, hydroxypropylcellulose (HPC), etc., but not limited thereto.
As used herein, the term "disintegrant" refers to a substance that is used to accelerate the disintegration of solid preparations such that an activator that shows efficacy in the preparation is released within a short period of time. Examples of the disintegrant may include carboxymethylcellulose-calcium (CMC-Ca), crospovidone, sodium starch glycolate, sodium croscarmellose, low substituted hydroxypropylcellulose, etc., but not limited thereto.
As used herein, the term "lubricant" refers to a substance that offers improved flow characteristics. Examples of the lubricant may include colloidal silica, magnesium stearate, stearic acid, talk, sodium stearyl fumarate, etc., but not limited thereto.
The pharmaceutical combination preparation of the present disclosure may be, for example, an oral solid preparation, preferably a bilayer tablet.
In another aspect of the present disclosure, the present disclosure provides a method for preparing a pharmaceutical combination preparation comprising telmisartan and (S)-amlodipine. The pharmaceutical combination preparation of the present disclosure may be prepared by any method known to those skilled in the art such as wet granulation method, direct compression, dry granulation, etc.
For example, the method of preparing a pharmaceutical combination preparation of the present disclosure by the wet granulation comprises the steps of preparing a binder solution; preparing a mixture by mixing a main ingredient with a diluent (or excipient); combining the binder solution with the mixture; and compressing the combination by drying, sieving, and lubrication.
Moreover, for example, the method of preparing a pharmaceutical combination preparation of the present disclosure by the direct compression comprises the steps of preparing a mixture by mixing a main ingredient with an excipient; and adding a disintegrant and a lubricant to the mixture, followed by lubrication and compression.
The pharmaceutical combination preparation of the present disclosure may be prepared as follows: in order to provide a telmisartan layer, for example, a solution prepared by dissolving alkaline components such as dried sodium carbonate in an appropriate solvent is sprayed onto an inert excipient and then dried to prepare an amorphous telmisartan granule composition, a granule composition of a layer comprising (S)-amlodipine is prepared, and then the two granule compositions are compressed to prepare the pharmaceutical combination preparation of the present disclosure.
Moreover, in another aspect of the present disclosure, the pharmaceutical combination preparation of the present disclosure can be effectively used for the purpose of preventing or treating a cardiovascular disease selected from the group consisting of hypertension, angina pectoris, arterial spasm, cardiac arrhythmia, cerebral infarction, heart hypertrophy, congestive heart failure, and myocardial infarction and, in particular, can be used to prevent or treat essential hypertension.
Additionally, the present disclosure provides a pharmaceutical composition comprising the pharmaceutical combination preparation. The pharmaceutical composition of the present disclosure has remarkable effect in preventing and treating cardiovascular diseases.
Further, the present disclosure provides a treatment method for cardiovascular diseases including administration of therapeutically effective dose of a pharmaceutical combination preparation comprising a first layer comprising telmisartan or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, and calcium silicate; and a second layer comprising (S)-amlodipine or a pharmaceutically acceptable salt thereof.
The treating method for cardiovascular diseases by using the pharmaceutical combination preparation of the present disclosure includes administration of the pharmaceutical combination preparation of the present disclosure in an amount of therapeutically effective dose. The term "therapeutically effective dose" stated in the present disclosure describes an amount of the combination preparation of the present disclosure that is effective in preventing or treating cardiovascular diseases. The pharmaceutical combination preparation of the present disclosure can be applied to a treatment method by additionally combining it with one or more therapeutic agents.
Also, the present disclosure provides a use of a pharmaceutical combination preparation comprising a first layer comprising telmisartan or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, and calcium silicate; and a second layer comprising (S)-amlodipine or a pharmaceutically acceptable salt thereof for preparation of medicaments for cardiovascular disease treatment. The acceptable additives supra can be mixed with the combination preparation of the present disclosure for preparation of medicaments.
Matters stated in regard of the combination preparation, composition, treatment method and use of the present disclosure are applied identically unless these are contradictory to each other.